Can Prostate Specific Antigen Velocity Thresholds Decrease Insignificant Prostate Cancer Detection?

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 112-117

  Loeb, Stacy ^a   Roehl, Kimberly A ^b   Helfand, Brian T ^c   Kan, Donghui ^c   Catalona, William J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

mass screening; prostate; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER SCREENING; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEMINAL VESICLE DISEASE; VELOCITY;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 71249150273     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.156     Document Type: Article

References (15)

1. Schroder F.H., Hugosson J., and Roobol M.J. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320
2. Sutcliffe P., Hummel S., Simpson E., et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess 13 (2009) iii
3. Loeb S., Sutherland D.E., D'Amico A.V., et al. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 72 (2008) 1116
4. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
5. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
6. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521
7. Moul J.W., Sun L., Hotaling J.M., et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 177 (2007) 499
8. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf Accessed September 2, 2009
9. Smith D.S., and Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152 (1994) 1732
10. Humphrey P.A., and Vollmer R.T. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10 (1997) 326
11. Ohori M., Wheeler T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714
12. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
13. Smith D.S., and Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163
14. Porter M.P., Stanford J.L., and Lange P.H. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Prostate 66 (2006) 1044
15. Loeb S., Roehl K.A., Nadler R.B., et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol 178 (2007) 2348